On the glutamine axis, iCCA cells frequently overexpress glutaminase-1 (GLS1), and preclinical work (e.g., the GLS1 inhibitor CB-839) has shown that suppression of glutamine metabolism reduces malignant phenotypes and may sensitize tumours to immunotherapeutic intervention (42). The gene discussed is GLS; the disease is neoplasm.